Figure 7.

Von Frey test evaluating chronic hypoalgesia reflecting oxaliplatin-induced neuropathy. Balb/c mice inoculated with CT26 cells treated by weekly intraperitoneal injection with vehicle (8 mice), oxaliplatin (8 mice, 10 mg/kg/week), OxPt-2-Mn1C1A (9 mice, 10 mg/kg/week), and Mn1C1A + oxaliplatin (9 mice, 10 mg/kg/week). (A) Mean Von Frey scores over the whole experiment, showing statistical significance between Mn1C1A + oxaliplatin with less hypoalgesia than oxaliplatin alone (p < 0.05). (B) Von Frey score evolution over time (days) in the different groups. The Von Frey basal score was the same in each group. In the oxaliplatin group, hypoalgesia appeared after the first oxaliplatin injection and worsened over time. In the OxPt-2-Mn1C1A group, hypoalgesia appeared later and with lower intensity, but no statistical difference was observed compared to oxaliplatin. In the Mn1C1A + oxaliplatin group, no hypoesthesia appeared at the end of the experiment. The difference was statistically significant and showed neuroprotective activity of Mn1C1A associated with oxaliplatin compared to oxaliplatin alone.